NCT04972227

Study to Assess the Safety and Pharmacokinetics of CY6463 in Participants With Stable Schizophrenia

A Double-blinded, Randomized, Placebo-controlled, Multiple-ascending-dose Study to Assess the Safety and Pharmacokinetics of CY6463 in Participants With Stable Schizophrenia

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 48 (actual)
• Sponsor: Tisento Therapeutics · Industry
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of this study is to evaluate the safety and tolerability of CY6463 when administered to participants with stable schizophrenia who are on a stable antipsychotic medication regimen

Conditions

• Schizophrenia

Interventions

Type	Name	Description
DRUG	CY6463	oral tablets
DRUG	Placebo	oral tablets

Timeline

• Start date: 2021-09-10
• Primary completion: 2022-04-18
• Completion: 2022-04-18
• First posted: 2021-07-22
• Last updated: 2024-08-13

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study